120 related articles for article (PubMed ID: 19240185)
1. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
2. ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen.
Wang L; Lyu Y; Li Y; Li K; Wen H; Feng C; Li N
Aging (Albany NY); 2021 Sep; 13(18):22286-22297. PubMed ID: 34536950
[TBL] [Abstract][Full Text] [Related]
3. Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy.
Lin Y; Yang S; Yang W; Cheng H; Chang X; Zhu Z; Feng J; Han J; Ren Q; Chang S; Liu S; Yu T; Hou B; Li P; Meng D; Zhang X; Qin H; Wang H
Eur J Med Res; 2023 Oct; 28(1):411. PubMed ID: 37814272
[TBL] [Abstract][Full Text] [Related]
4. The MQRG score: a novel prognostic tool for adrenocortical carcinoma patients based on mitochondrial quality.
Chen T; Wang Y; Chen X; Zheng W; Guo W; Liang Q; Wang J; Chen Z; Zhou Y; Xiao L
Front Endocrinol (Lausanne); 2024; 15():1222281. PubMed ID: 38505747
[TBL] [Abstract][Full Text] [Related]
5. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease.
Libé R; Huillard O
Cancer Treat Res Commun; 2023; 37():100759. PubMed ID: 37690343
[TBL] [Abstract][Full Text] [Related]
6. Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis.
Vanbrabant T; Fassnacht M; Assie G; Dekkers OM
Eur J Endocrinol; 2018 Dec; 179(6):429-436. PubMed ID: 30325179
[TBL] [Abstract][Full Text] [Related]
7. DNA Damage Repair Proteins, HSP27, and Phosphorylated-HSP90α as Predictive/Prognostic Biomarkers of Platinum-based Cancer Chemotherapy: An Exploratory Study.
Sottile ML; Cuello-Carrión FD; Gómez LC; Semino S; Ibarra J; García MB; Gonzalez L; Vargas-Roig LM; Nadin SB
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):425-434. PubMed ID: 35639358
[TBL] [Abstract][Full Text] [Related]
8. High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study.
Catalano R; Altieri B; Angelousi A; Arosio M; Bravi F; Canu L; Croci GA; Detomas M; Esposito E; Ferrante E; Ferrero S; Fuss CT; Kaltsas G; Kimpel O; Landwehr LS; Luconi M; Morelli V; Nesi G; Nozza E; Sbiera S; Serban AL; Ronchi CL; Mantovani G; Peverelli E
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068896
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma.
Lippert J; Smith G; Appenzeller S; Landwehr LS; Prete A; Steinhauer S; Asia M; Urlaub H; Elhassan YS; Kircher S; Arlt W; Fassnacht M; Altieri B; Ronchi CL
Eur J Endocrinol; 2024 Mar; 190(3):234-247. PubMed ID: 38451242
[TBL] [Abstract][Full Text] [Related]
10. Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma.
Fuss CT; Other K; Heinze B; Landwehr LS; Wiegering A; Kalogirou C; Hahner S; Fassnacht M
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830848
[TBL] [Abstract][Full Text] [Related]
11. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021.
Grisanti S; Cosentini D; Sigala S; Berruti A
Curr Opin Oncol; 2022 Jan; 34(1):19-28. PubMed ID: 34669649
[TBL] [Abstract][Full Text] [Related]
12. Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Obermayr E; Mohr T; Schuster E; Braicu EI; Taube E; Sehouli J; Vergote I; Pujade-Lauraine E; Ray-Coquard I; Harter P; Wimberger P; Joly-Lobbedez F; Mahner S; Moll UM; Concin N; Zeillinger R
Int J Cancer; 2024 Apr; ():. PubMed ID: 38676430
[TBL] [Abstract][Full Text] [Related]
13. PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma.
Warmington E; Smith G; Chortis V; Liang R; Lippert J; Steinhauer S; Landwehr LS; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Altieri B; Foster PA; Ronchi CL
Endocr Connect; 2024 Jan; 13(1):. PubMed ID: 37992487
[TBL] [Abstract][Full Text] [Related]
14. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
[TBL] [Abstract][Full Text] [Related]
15. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
16. Role and mechanism of miR-187 in human cancer.
Peng W; Sha H; Sun X; Zou R; Zhu Y; Zhou G; Feng J
Am J Transl Res; 2020; 12(9):4873-4884. PubMed ID: 33042395
[TBL] [Abstract][Full Text] [Related]
17. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical carcinoma - towards genomics guided clinical care.
Crona J; Beuschlein F
Nat Rev Endocrinol; 2019 Sep; 15(9):548-560. PubMed ID: 31147626
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Jing C; Li H; Du Y; Cao H; Liu S; Wang Z; Ma R; Feng J; Wu J
Mol Med Rep; 2019 Feb; 19(2):1092-1100. PubMed ID: 30535504
[TBL] [Abstract][Full Text] [Related]
20. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
